Biogen Inc (BIIB) is a publicly traded drug manufacturers - general business based in the US which employs around 7,550 staff. Biogen is listed on the NASDAQ and traded in US dollars. Its current price of $207.88 is 2.0% down on its price a month ago ($212.02).
Both exchange rates and share prices fluctuate in real time, so the costs estimated here should be considered as a guide only. They don't factor in spreads, which can be hard to pin down. Always refer to the platform itself for availability and pricing.
Quantity of shares
| Platform | Finder score | Account fee | Min. initial deposit | Trade cost | Link |
|---|---|---|---|---|---|
 |
4.39 ★★★★★ |
£0 | $100 | £836.10 |
Go to siteCapital at risk
|
 |
3.75 ★★★★★ |
0.12% per year | £0 | £834.08 |
Go to siteCapital at risk
|
 |
4.3 ★★★★★ |
£0 | £0 | £836.10 |
Go to siteCapital at risk
|
 |
4.2 ★★★★★ |
£0 | £1 | £852.21 |
Go to siteCapital at risk
|
 |
4.34 ★★★★★ |
0% - 0.25% | £100 | N/A |
Go to siteCapital at risk
|
 |
4.1 ★★★★★ |
£0 | £0 | N/A |
Read reviewCapital at risk
|
 |
4.4 ★★★★★ |
£0 | £0 | £836.10 |
Read reviewCapital at risk
|
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Buying shares in just one company is generally considered a riskier bet than investing in a range of investments - AKA a "diversified portfolio". Experts generally recommend holding a mix of investments in specific assets and funds. Funds are ready-made portfolios of multiple companies' shares (potentially including Biogen), and the idea is that drops in the value of one constituent company's share price might be offset by rises in others.
Biogen is a major part of the NASDAQ, so it's included in many global funds and investment trusts, as well as tracker-style exchange traded funds (ETFs).
| Icon | Fund | 5-year performance | 1-year performance (to October 2023) | Link to invest |
|---|---|---|---|---|
 | Invesco S&P 500 (SPXP) | 70.17% | 10.90% | Capital at risk |
 | Xtrackers S&P 500 Swap (XSPX) | 69.98% | 10.83% | Capital at risk |
 | HSBC S&P 500 (HSPX) | 68.59% | 10.87% | Capital at risk |
 | Vanguard S&P 500 (VUSA) | 68.24% | 10.73% | Capital at risk |
 | iShares Core S&P 500 (CSP1) | 68.20% | 10.73% | Invest with eToroCapital at risk |
 | SPDR S&P 500 ETF (SPX5) | 67.96% | 10.70% | Capital at risk |
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Over the last 12 months, Biogen's shares have ranged in value from as little as $189.44 up to $319.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is -0.009. This would suggest that Biogen's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Biogen has bucked the trend.
Historical closes compared with the last close of $207.88
| 1 week (2024-04-18) | 6.95% |
|---|---|
| 1 month (2024-03-25) | -1.95% |
| 3 months (2024-01-25) | -15.09% |
| 6 months (2023-10-25) | -13.77% |
| 1 year (2023-04-25) | -27.83% |
| 2 years (2022-04-24) | -3.10% |
| 3 years (2021-04-25) | -22.85% |
| 5 years (2019-04-25) | -9.83% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Biogen P/E ratio, PEG ratio and EBITDA
Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Biogen shares trade at around 25x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Biogen's P/E ratio is best considered in relation to those of others within the industry or those of similar companies.
Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.2424. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Biogen's PEG ratio in relation to those of similar companies.
Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $2.4 billion (£1.9 billion).
The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
Sign up for weekly expert share tips
Join 100,000 subscribers who are notified about expert share tips. Plus a chance to win £800!
By signing up you agree to receive emails from Finder and to the privacy policy and terms & conditions.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Ever wondered how to buy shares in Canopy Growth? We explain how and compare a range of providers that can give you access to many brands, including Canopy Growth.
Ever wondered how to buy shares in Green Thumb Industries? We explain how and compare a range of providers that can give you access to many brands, including Green Thumb Industries.
Ever wondered how to buy shares in Curaleaf Holdings? We explain how and compare a range of providers that can give you access to many brands, including Curaleaf Holdings.
Ever wondered how to buy shares in Genesis Healthcare? We explain how and compare a range of providers that can give you access to many brands, including Genesis Healthcare.
Ever wondered how to buy shares in Allergy Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Allergy Therapeutics.
Ever wondered how to buy shares in 4D pharma? We explain how and compare a range of providers that can give you access to many brands, including 4D pharma.
Ever wondered how to buy shares in Aurora Cannabis? We explain how and compare a range of providers that can give you access to many brands, including Aurora Cannabis.
Thinking about buying shares in Evgen Pharma? We explain how to do it and compare a range of providers who will give you access to global markets.
Ever wondered how to buy shares in Intuitive Surgical? We explain how and compare a range of providers that can give you access to many brands, including Intuitive Surgical.
Ever wondered how to buy shares in Stryker? We explain how and compare a range of providers that can give you access to many brands, including Stryker.